



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/17 ^(2006.01) **A61K 38/39** ^(2006.01)
A61K 45/06 ^(2006.01) **A61K 48/00** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 31/513** ^(2006.01)
A61K 31/4745 ^(2006.01) **A61K 31/7048** ^(2006.01)
A61K 33/24 ^(2006.01)

(48) Corrigendum issued on:
21.12.2016 Bulletin 2016/51

(45) Date of publication and mention
of the grant of the patent:
13.01.2016 Bulletin 2016/02

(21) Application number: **12183770.2**

(22) Date of filing: **14.01.2004**

(54) **Cancer therapy sensitizer**
Sensibilisator für Krebstherapie
Sensibilisateur de thérapie anticancéreuse

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR**

(30) Priority: **14.01.2003 US 440009 P**

(43) Date of publication of application:
27.02.2013 Bulletin 2013/09

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
04702173.8 / 1 594 433

(73) Proprietor: **Dana-Farber Cancer Institute, Inc.**
Boston, MA 02115-5450 (US)

(72) Inventors:
• **Tai, Isabelle, T.**
Vancouver, British Columbia V6Z 3A9 (CA)
• **Chen, Lan Bo**
Lexington, MA 02420 (US)

(74) Representative: **D Young & Co LLP**
120 Holborn
London EC1N 2DY (GB)

(56) References cited:
• **STEIN U ET AL: "Reversal of Multidrug
Resistance by Transduction of Cytokine Genes
into Human Colon Carcinoma Cells", JOURNAL
OF THE NATIONAL CANCER INSTITUTE.
MONOGRAPHS, SERVICE, NATIONAL
INSTITUTES OF HEALTH, WASHINGTON, DC,
vol. 88, no. 19, 2 October 1996 (1996-10-02), pages
1383-1392, XP002493063, ISSN: 1052-6773**
• **GARY K YIU ET AL: "SPARC (SECRETED
PROTEIN ACIDIC AND RICH IN CYSTEINE)
INDUCES APOPTOSIS IN OVARIAN CANCER
CELLS", AMERICAN JOURNAL OF PATHOLOGY;
[10640], AMERICAN SOCIETY FOR
INVESTIGATIVE PATHOLOGY, US, vol. 159, no.
2, 1 August 2001 (2001-08-01), pages 609-622,
XP002983766, ISSN: 0002-9440**
• **CHLENSKI A ET AL: "SPARC IS A KEY
SCHWANNIAN-DERIVED INHIBITOR
CONTROLLING NEUROBLASTOMA TUMOR
ANGIOGENESIS", CANCER RESEARCH,
AMERICAN ASSOCIATION FOR CANCER
RESEARCH, US, vol. 62, 15 December 2002
(2002-12-15), pages 7357-7363, XP002986916,
ISSN: 0008-5472**

- DHANESUAN N ET AL: "Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition", BREAST CANCER RESEARCH, CURRENT SCIENCE, LONDON, GB, vol. 75, no. 1, 1 September 2002 (2002-09-01), pages 73-85, XP002493062, ISSN: 1465-5411, DOI: 10.1023/A:1016536725958
- TAI ISABELLA T ET AL: "Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 115, no. 6, 1 June 2005 (2005-06-01), pages 1492-1502, XP002488747, ISSN: 0021-9738, DOI: 10.1172/JCI23002